A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy

In the absence of a proven effective vaccine preventing infection by SARS-CoV-2, or a proven drug to treat COVID-19, the positive results of passive immune therapy using convalescent serum provide a strong lead. We have developed a new class of tetravalent, biparatopic therapy, 89C8-ACE2. It combine...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Xiaoniu, Luo, Yi, Huang, Xi, Lee, Suki M. Y., Yuan, Zhijun, Tang, Yongzhou, Chen, Liandi, Wang, Chao, Wu, Fan, Xu, Yifeng, Jiang, Wenchao, Gao, Wei, Song, Xuedong, Yan, Yao, Pang, Tuling, Chen, Cheng, Zou, Yuefeng, Fu, Weihui, Wan, Liping, Gilbert-Jaramillo, Javier, Knight, Michael, Tan, Tiong Kit, Rijal, Pramila, Townsend, Alain, Sun, Joanne, Liu, Xiaolin, James, William, Tsun, Andy, Xu, Yingda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531490/
https://www.ncbi.nlm.nih.gov/pubmed/32804015
http://dx.doi.org/10.1080/19420862.2020.1804241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531490/
https://www.ncbi.nlm.nih.gov/pubmed/32804015
http://dx.doi.org/10.1080/19420862.2020.1804241

Ejemplares similares